Free Trial
→ The warning signs most investors see too late (From Weiss Ratings) (Ad)tc pixel
OTCMKTS:BIOVF

Swedish Orphan Biovitrum Q1 2025 Earnings Results & Report

Swedish Orphan Biovitrum logo
$45.72 0.00 (0.00%)
As of 11/6/2026

Swedish Orphan Biovitrum beat analyst earnings expectations but missed on revenue in its Q1 2025 results, released April 29, 2025. The company reported EPS of $0.26 versus the $0.2152 consensus estimate, while revenue of $641.33 million fell short of the $644.12 million estimate by $2.79 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens

Swedish Orphan Biovitrum EPS Results

Actual EPS
$0.26
Consensus EPS
$0.2152
Beat/Miss
Beat by +$0.0448
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Swedish Orphan Biovitrum Revenue Results

Actual Revenue
$641.33 million
Expected Revenue
$644.12 million
Beat/Miss
Missed by -$2.79 million
YoY Revenue Growth
N/A

Conference Call Resources

Swedish Orphan Biovitrum Q1 2025 Earnings FAQ

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) reported earnings of $0.26 per share for Q1 2025, beating the consensus estimate of $0.2152. The report was announced on Tuesday, April 29, 2025.

Swedish Orphan Biovitrum reported revenue of $641.33 million for Q1 2025, against a consensus estimate of $644.12 million.

Swedish Orphan Biovitrum Earnings Headlines

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Stock Rated "Moderate Buy" by Sell-Side Analysts
November 5 at 2:58 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31179304
Swedish Orphan Biovitrum AB: Börje Ekholm is proposed as new Chair of the Sobi Board of Directors
October 29, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-10/69981401-swedish-orphan-biovitrum-ab-boerje-ekholm-is-proposed-as-new-chair-of-the-sobi-board-of-directors-008.htm
A monthly income idea that does not require selling shares
A $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start with $150,000 and it's gone in under six years. A new Prudential survey of more than 3,000 Americans over 50 found 86% don't feel free to spend their savings on things they enjoy. Tim Plaehn, who has advised investors since the 1980s, is tracking a monthly income fund built on major U.S. companies that pays cash without requiring investors to sell shares.tc pixel
November 8 at 1:00 AM  |  Investors Alley (Ad)
Börje Ekholm is proposed as new Chair of the Sobi Board of Directors
October 29, 2026  |  marketscreener.comM
Swedish Orphan Biovitrum Swings To Profit In Q3; Updates FY26 View; Stock Up 2.9%
October 28, 2026  |  rttnews.comhttps://www.rttnews.com/3703306/swedish-orphan-biovitrum-swings-to-profit-in-q3-updates-fy26-view-stock-up-2-9.aspx
Harry Gillis Raises Swedish Orphan Biovitrum Price Target to SEK570, Reiterates Buy on Tryngolza-Led Growth Upside
October 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/ratings/harry-gillis-raises-swedish-orphan-biovitrum-price-target-to-sek570-reiterates-buy-on-tryngolza-led-growth-upside-ratings-news?utm_source=marketbeat.com&utm_medium=referral
See More Swedish Orphan Biovitrum Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Swedish Orphan Biovitrum? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Swedish Orphan Biovitrum and other key companies, straight to your email.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) AB, known as Sobi, is a Swedish biopharmaceutical company focused on developing and providing treatments for rare and other serious diseases. Its work centers on hematology, immunology and specialized medicines for conditions with limited treatment options.

Sobi’s portfolio includes therapies for blood disorders such as hemophilia, as well as treatments for rare inflammatory and immune-related conditions. The company also develops and commercializes medicines for other rare diseases, working with research and commercial partners where appropriate.

The company was formed in 2010 when Biovitrum acquired Swedish Orphan and adopted the Swedish Orphan Biovitrum name. Based in Sweden, Sobi serves patients through operations and partnerships across Europe, North America and other international markets.

View Swedish Orphan Biovitrum Profile
Earnings Tools